MINAL PATEL: Open Payments
NPI 1871681056 · WYOMISSING, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,566 in 118 payments from 19 companies in 2025. Trend: 2023 $1,963 · 2024 $2,037 · 2025 $2,566
Food & beverage: $2,566
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 48 | $488 |
| Madrigal Pharmaceuticals | 8 | $420 |
| Janssen Biotech, Inc. | 11 | $334 |
| GENZYME CORPORATION | 8 | $260 |
| PFIZER INC. | 14 | $174 |
| Gilead Sciences, Inc. | 3 | $156 |
| Ardelyx, Inc. | 1 | $150 |
| Phathom Pharmaceuticals, Inc. | 3 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $135 |
| Regeneron Healthcare Solutions, Inc. | 5 | $100 |
Products named: REZDIFFRA, DUPIXENT, TREMFYA, RINVOQ, IBSRELA, VOQUEZNA, ENTYVIO, Livdelzi.
Industry payments across PA — which companies pay providers there.
